Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in high risk invasive urothelial carcinoma
NCT02632409Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2016
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of nivolumab in urothelial carcinoma (UC), sponsored by Bristol Myers Squibb. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02632409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632409.